Regulatory 2025-09-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-09-22 | Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million PDF Report Presentation Webcast
Regulatory 2025-09-22 | Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK 30 Million PDF Report Presentation Webcast
Regulatory 2025-09-02 | Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2025-04-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-04-16 | Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1 PDF Report Presentation Webcast
Regulatory 2024-11-29 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-11-22 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program PDF Report Presentation Webcast
2024-10-01 | Ascelia Pharma Announces Acceptance of Orviglance SPARKLE Study Primary Results as Oral Presentation in Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
Regulatory 2024-09-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-09-13 | Ascelia Pharma Resolves on a Directed Issue of Convertibles of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2024-09-05 | Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue PDF Report Presentation Webcast
Regulatory 2024-09-04 | Ascelia Pharma Announces Preliminary Outcome in Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-16 | Ascelia Pharma Announces Prospectus in Connection with Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-09 | Ascelia Pharma Announces Final Terms of Rights Issue PDF Report Presentation Webcast
Regulatory 2024-07-10 | Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® PDF Report Presentation Webcast
Regulatory 2024-02-04 | Ascelia Pharma Secures Financing of up to SEK 35 Million PDF Report Presentation Webcast
Regulatory 2023-11-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
